Latest news for VAT Group (OTC:VACNY) Stock

VAT Group AG manufactures and sells valves that are used in machines. The company has two segments. The Valves segment is focused on its core vacuum valve technology and consists of three business units aligned with its markets: Semiconductors, Display & Solar industries. The second segment, Global Service, supplies a growing range of service products and solutions to help customers. The company derives maximum revenue from the Valves segment. The company derives maximum revenue from China.

VAT Group AG

Providing a diverse range of perspectives from bullish to bearish, 11 analysts have published ratings on Coursera (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COUR#NYSE">COUR</a>) in the last three months.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $10.93, with a high estimate of $18.00 and a low estimate of $7.25. This current average represents a 28.19% decrease from the previous average price target of $15.22. 
<img src="https://www.benzinga.com/files/images/story/2024/1732536020_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of Coursera by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bryan Smilek</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Neutral</td>
<td>$8.00</td>
<td>-</td>
</tr>
<tr>
<td>Sarang Vora</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$15.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$10.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Jason Celino</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$11.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$7.25</td>
<td>$9.00</td>
</tr>
<tr>
<td>Yi Fu Lee</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Jeffrey Silber</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$9.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Josh Baer</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$11.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Sarang Vora</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Nafeesa Gupta</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$11.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Coursera. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Coursera compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Coursera's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Coursera's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/COUR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Coursera analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Coursera Better</h2>
Coursera Inc is an online learning platform that connects learners, educators, and institutions with the goal of providing educational content that is affordable, accessible, and relevant. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The company operates through three reporting segments: Consumer, Enterprise, and Degrees. The majority of revenue is generated from the Consumer segment. The consumer segment targets individual learners seeking to obtain hands-on learning, gain valuable job skills, receive professional-level certifications, and otherwise increase their knowledge to start or advance their careers.
<h3>Coursera: Financial Performance Dissected</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Coursera's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 6.37%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Coursera's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -7.77%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -2.32%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -1.51%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.01, Coursera adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

COUR

What 11 Analyst Ratings Have To Say About Coursera

Across the recent three months, 25 analysts have shared their insights on Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">12</td>
<td align="right">8</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">10</td>
<td align="right">7</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Snowflake, revealing an average target of $179.76, a high estimate of $225.00, and a low estimate of $125.00. Witnessing a positive shift, the current average has risen by 7.17% from the previous average price target of $167.74.
<img src="https://www.benzinga.com/files/images/story/2024/1732536010_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Snowflake. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Announces</td>
<td>Outperform</td>
<td>$190.00</td>
<td>-</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$225.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Ki Bin Kim</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$210.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$160.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Gregg Moskowitz</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$195.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>J. Derrick Wood</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Brad Zelnick</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$188.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Bradley Sills</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$185.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$172.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>Ittai Kidron</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$180.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$150.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Kirk Materne</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$190.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Eric Heath</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$185.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Blair Abernethy</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$186.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$185.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Blair Abernethy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$183.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Eric Heath</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$150.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>Brian White</td>
<td>Monness, Crespi, Hardt</td>
<td>Announces</td>
<td>Buy</td>
<td>$140.00</td>
<td>-</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Blair Abernethy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Karl Keirstead</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$125.00</td>
<td>$155.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Snowflake. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Snowflake compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Snowflake's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Snowflake's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SNOW/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Snowflake analyst ratings.</a>
<h2>Discovering Snowflake: A Closer Look</h2>
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that went public in 2020. To date, the company has over 3,000 customers, including nearly 30% of the Fortune 500. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to buy and ingest data, while its data solutions can be hosted on various public clouds.
<h3>Snowflake: Delving into Financials</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Snowflake's remarkable performance in 3 months is evident. As of 31 October, 2024, the company achieved an impressive revenue growth rate of 8.43%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -34.42%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Snowflake's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -9.19%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Snowflake's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -4.28%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Snowflake's debt-to-equity ratio is below the industry average. With a ratio of 0.89, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SNOW

Where Snowflake Stands With Analysts

Citigroup analyst Keith Horowitz upgrades U.S. Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>) from Neutral to Buy and raises the price target from $49 to $65.

News

Upgrades

Price Target

Citigroup Upgrades U.S. Bancorp to Buy, Raises Price Target to $65

HC Wainwright &amp; Co. analyst Yi Chen downgrades Mainz Biomed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNZ#NASDAQ">MYNZ</a>) from Buy to Neutral.

Downgrades

MYNZ

HC Wainwright & Co. Downgrades Mainz Biomed to Neutral

As a result of the independent investigation and forensic analysis, the company identified that a single employee with responsibility for small package delivery expense accounting intentionally made erroneous accounting accrual entries to hide approximately $132 to $154 million of cumulative delivery expenses from the fourth quarter of 2021 through fiscal quarter ended November 2, 2024.
&nbsp;During this same time period, the company recognized approximately $4.36 billion of delivery expenses. There is no indication that the erroneous accounting accrual entries had any impact on the company's cash management activities or vendor payments.&nbsp;
The individual who engaged in this conduct is no longer employed by the company. The investigation has not identified involvement by any other employee.
&nbsp;

Macy's Says Identified An Issue Related To Delivery Expenses In One Of Its Accrual Accounts; Consequently Initiated An Independent Investigation

Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZeneca's Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS) versus abiraterone and ADT with placebo in patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC).
Overall survival (OS) data were immature at the time of this analysis; however, the Truqap combination showed an early trend towards an OS improvement versus abiraterone and ADT with placebo. The trial will continue as planned to further assess OS as a key secondary endpoint.
Prostate cancer is the second most prevalent cancer in men and the fifth leading cause of male cancer death globally.1 Only one third of patients with metastatic prostate cancer survive five years after diagnosis.2 Newly diagnosed mHSPC is an aggressive form of the disease associated with poor outcomes and survival.3,4 Approximately 200,000 patients are diagnosed with mHSPC each year, and one in four have PTEN-deficient tumours.5 Patients with a tumour biomarker of PTEN deficiency have a particularly poor prognosis.6
Karim Fizazi, MD, PhD, Institut Gustave Roussy, and University of Paris Saclay in Villejuif, France, and principal investigator for the trial said: "Patients with this aggressive form of prostate cancer with tumour PTEN deficiency currently face a particularly poor prognosis, and there is an urgent need for new treatments that improve upon current therapies. The results seen with capivasertib in combination with abiraterone-prednisone and androgen deprivation therapy in the CAPItello-281 trial represent a step forward for these patients."
Susan Galbraith, Executive Vice President, Oncology R&amp;D, AstraZeneca, said: "These results show for the first time, that adding an AKT inhibitor to a standard-of-care therapy can provide benefit to patients with a biomarker of PTEN-deficient metastatic hormone-sensitive prostate cancer. By targeting a key driver of the disease, we have been able to improve upon current therapies and demonstrate the potential role of this combination in an area of critical unmet need. It will be important to see greater maturity in key secondary endpoints including overall survival."
The safety profile of&nbsp;Truqap&nbsp;in combination with abiraterone and ADT in CAPItello-281 was broadly consistent with the known profile of each medicine.
Data will be presented at a forthcoming medical meeting and shared with global regulatory authorities.
Notes
Prostate cancer Prostate cancer is the second most prevalent cancer in men and the fifth leading cause of male cancer death globally, with an incidence of more than 1.4 million and approximately 397,000 deaths in 2022.1
Metastatic prostate cancer is associated with a significant mortality rate, with only one third of patients surviving five years after diagnosis.2 Development of prostate cancer is often driven by male sex hormones called androgens, including testosterone.7
Metastatic hormone-sensitive prostate cancer In patients with mHSPC, also known as metastatic castration-sensitive prostate cancer (mCSPC), prostate cancer cells need high levels of androgens to drive cancer growth.4,7 Hormone therapies, such as ADT, are widely used to block the action of male sex hormones and lower the levels of androgens in the body.4,8 However, resistance to these therapies is common and there is a need to extend their use to delay disease progression and castration resistance, where the prostate cancer grows and spreads to other parts of the body despite the use of these therapies.3,4,8
In patients with de novo mHSPC, the cancer has spread to distant parts of the body at the time of first diagnosis.9
PTEN-loss or deficiency fuels the growth of cancer cells, leading to dysregulation of the PI3K/AKT pathway, and is associated with poor outcomes in patients with prostate cancer.6,10
CAPItello-281 CAPItello-281 is a Phase III, double-blind, randomised trial evaluating the efficacy and safety of Truqap in combination with abiraterone and ADT versus abiraterone and ADT in combination with placebo in the treatment of patients with PTEN-deficient de novo mHSPC.
The global trial enrolled 1,012 adult patients with histologically confirmed de novo hormone-sensitive prostate adenocarcinoma and PTEN deficiency as confirmed by central testing. The primary endpoint of the CAPItello-281 trial is rPFS as assessed by investigator, with OS as a secondary endpoint.
Truqap Truqap is a first-in-class, potent, adenosine triphosphate (ATP)-competitive inhibitor of all three AKT isoforms (AKT1/2/3). Truqap 400mg is administered twice daily according to an intermittent dosing schedule of four days on and three days off. This was chosen in early phase trials based on tolerability and the degree of target inhibition.
Truqap is approved in the US, EU, Japan and several other countries for the treatment of adult patients with HR-positive (or ER-positive), HER2-negative locally advanced or metastatic breast cancer with one or more biomarker alterations (PIK3CA, AKT1 or PTEN) following recurrence or progression on or after an endocrine-based regimen based on the results from the CAPItello-291 trial. Truqap is also approved in Australia for the treatment of adult patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer following recurrence or progression on or after an endocrine based regimen based on these trial results.
Truqap is currently being evaluated in Phase III trials for the treatment of breast cancer (CAPItello-292) and prostate cancer (CAPItello-280 and CAPItello-281) in combination with established treatments.
Truqap was discovered by AstraZeneca subsequent to a collaboration with Astex Therapeutics (and its collaboration with the Institute of Cancer Research and Cancer Research Technology Limited).
AstraZeneca in oncology AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.
The Company's focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practice of medicine and transform the patient experience.
AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

AstraZeneca's Truqap Demonstrates Progress in Advanced Prostate Cancer Treatment

Citigroup analyst Anthony Pettinari reinstates Berry Global Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BERY#NYSE">BERY</a>) with a Neutral and announces $76 price target.

Initiation

BERY

Citigroup Reinstates Neutral on Berry Global Gr, Announces $76 Price Target

Macy's Says November Comparable Sales Are Trending Ahead Of Q3 Levels Across Nameplates

Guidance

Macy's Delays Q3 Earnings Release And Conference Call; Reports Preliminary Net Sales Decrease Of 2.4% To $4.742Bn, With Comparable Sales Down 2.4% On An Owned Basis

Bath &amp; Body Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) reported quarterly earnings of $0.49 per share which beat the analyst consensus estimate of $0.47 by 4.26 percent. This is a 2.08 percent increase over earnings of $0.48 per share from the same period last year. The company reported quarterly sales of $1.610 billion which beat the analyst consensus estimate of $1.579 billion by 1.98 percent. This is a 3.07 percent increase over sales of $1.562 billion the same period last year.

Earnings

Earnings Beats

BBWI

Bath & Body Works Q3 2024 Adj. EPS $0.49 Beats $0.47 Estimate, Sales $1.610B Beat $1.579B Estimate

Citigroup analyst Keith Horowitz downgrades M&amp;T Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTB#NYSE">MTB</a>) from Buy to Neutral and raises the price target from $220 to $230.

Citigroup Downgrades M&T Bank to Neutral, Raises Price Target to $230

Needham analyst Serge Belanger reiterates Viridian Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRDN#NASDAQ">VRDN</a>) with a Buy and maintains $38 price target.

Reiteration

VRDN

Needham Reiterates Buy on Viridian Therapeutics, Maintains $38 Price Target

Nu Holdings Ltd. ("Nu Holdings"of "Company") informs its shareholders and the market that the Financial Superintendence of Colombia ("SFC") has formally approved the merger of its Colombian entity Nu Colombia S.A. into Nu. Colombia Compañía de Financiamiento S.A..
The merger, which consolidates the accounts and operations in the country into one single entity (Nu. Colombia Compañía de Financiamiento S.A.) supervised by the SFC, reinforces the Company's long-term vision and commitment to Colombia and will allow the expansion of its portfolio of products and services in the future.

Nu Holdings Consolidates Colombian Operations, Expanding Future Financial Services

Needham analyst Scott Berg reiterates Workday (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) with a Buy and maintains $300 price target.

WDAY

Needham Reiterates Buy on Workday, Maintains $300 Price Target

Freightos Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGO#NASDAQ">CRGO</a>), a leading vendor-neutral digital booking and payment platform for the international freight industry, today announced that Ran Shalev, Chief Financial Officer, has decided to conclude his tenure effective December 31, 2024, to pursue another role. The company is in the process of a search for a successor. In order to ensure continuity, Mr. Shalev has agreed following his departure to actively assist with ongoing operations and with handover throughout Q1.
&nbsp;
Mr. Shalev has served as Freightos' CFO since 2016, overseeing the company's financial operations during a transformative period that included its public listing on Nasdaq, the successful execution of multiple strategic acquisitions, and consistent growth in revenue and transaction volumes.

Management

CRGO

Freightos To Deaprt As CFO Effective December 31 To Pursue Another Job, Company In Process Of Finding A Successor

<ul>
<li>Amglidia is a proprietary, patented liquid product that was developed for the treatment of neonatal diabetes mellitus by AMMTeK, a French biotechnology company. The product was approved by the EMA in 2018.&nbsp;</li>
<li>The product has already been granted Orphan Drug Designation by the U.S. FDA. Neonatal diabetes mellitus is a rare condition estimated to impact approximately 300 patients in the United States.&nbsp;</li>
<li>Currently, there are no FDA-approved oral treatment options and as a result, U.S. patients frequently either rely on compounded products that are not FDA-approved or administer products off-label by making homemade suspensions.</li>
<li>AMMTeK has conducted a post-approval study tracking five years of real-world safety and efficacy in European patients, which will be used to support Eton's NDA submission. Eton plans to hold a meeting with the FDA in the first quarter of 2025 and anticipates submitting an NDA for the product in 2026.</li>
</ul>

Health Care

General

ETON

Eton Pharmaceuticals Has Acquired The Us Rights To Amglidia (Glyburide Oral Suspension, Known As Glibenclamide In Europe) For Neonatal Diabetes Mellitus From AMMTeK, Potential US Marketing Application Submission Expected In 2026

Loop Capital analyst Garik Shmois downgrades Eagle Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXP#NYSE">EXP</a>) from Buy to Hold and maintains the price target from $315 to $315.

Loop Capital Downgrades Eagle Materials to Hold, Maintains Price Target to $315

Wolfe Research analyst Andrew Rosivach upgrades Jones Lang LaSalle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JLL#NYSE">JLL</a>) from Peer Perform to Outperform and announces $353 price target.

Wolfe Research Upgrades Jones Lang LaSalle to Outperform, Announces $353 Price Target

Merck (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), known as MSD outside of the United States and Canada, announced today positive topline results from the Phase 3 ZENITH study evaluating WINREVAIR (sotatercept-csrk) in adults with pulmonary arterial hypertension (PAH, WHO&#x2A; Group 1) functional class (FC) III or IV at high risk of mortality. ZENITH met its primary endpoint of time to first morbidity or mortality event (all-cause death, lung transplantation, or PAH worsening related hospitalization of ≥ 24 hours). In the study, WINREVAIR demonstrated a statistically significant and clinically meaningful reduction in the risk of morbidity or mortality events compared to placebo, both on top of background PAH therapy. Based on the strength of these results, an independent data monitoring committee has recommended ZENITH be stopped early and all participants be offered the opportunity to receive WINREVAIR through the SOTERIA open-label extension study. In preliminary assessment, adverse events and serious adverse events were balanced between the treatment groups.
"PAH is a serious, progressive disease with a high incidence of morbidity and mortality," said Dr. Eliav Barr, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. "Based on the primary endpoint demonstrating overwhelming efficacy, all ZENITH study participants will be offered the opportunity to receive WINREVAIR. These findings are impressive, set a high evidentiary bar for studies of future candidates developed for the treatment of PAH and support the potential of WINREVAIR to be practice-changing in the management of PAH."
"The ZENITH trial was designed to evaluate whether the addition of WINREVAIR, an activin signaling inhibitor, could reduce the risk of death, lung transplantation, or PAH hospitalizations for patients living with advanced PAH," said Dr. Vallerie McLaughlin&#x2A;&#x2A;, Kim A Eagle MD Endowed Professor of Cardiovascular Medicine and Director, Pulmonary Hypertension Program, University of Michigan in Ann Arbor. "This is the first study in PAH in which the interim analysis led to an early conclusion of the study due to overwhelming efficacy. WINREVAIR has brought significant optimism to the field, and we thank the investigators and patients for being part of this important study."
WINREVAIR is currently approved in the U.S. and 36 countries based on the results from the Phase 3 STELLAR trial. Most recently, in November of this year, WINREVAIR was submitted for approval in Japan based on the STELLAR trial and results from an open-label Phase 3 study in Japanese patients.
Results from ZENITH will be presented at an upcoming medical meeting and will be submitted to regulatory authorities.

Merck's WINREVAIR Achieves Results in PAH Study, Trial Ends Early on Efficacy

Wolfe Research analyst Andrew Rosivach downgrades Newmark Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRK#NASDAQ">NMRK</a>) from Outperform to Peer Perform.

NMRK

Wolfe Research Downgrades Newmark Group to Peer Perform

European stocks with margins at risk of contracting as pricing deteriorates - JPM

VAT Group AG reports Q4 results

VAT Group AG 2023 Q4 - Results - Earnings Call Presentation

VAT Group AG (VACNY) Q4 2023 Earnings Call Transcript

VAT Group AG goes ex dividend tomorrow

VAT Group AG reports H1 results, sees strong demand from semiconductor industry

VAT Group AG (VACNY) Q2 2024 Earnings Call Transcript

A Substantially Weaker Macro Environment May Be The Only Thing That Can Slow Atlas Copco

Janus Henderson European Focus Fund Q2 2024 Commentary

China-exposed European stocks that could see a lift amid growth expectations

AAUKF

ALFVF

ALFVY

AMSYF

ANFGF

ASMIY

ASML

ASMXF

ATLKY

AZNCF

BDRFF

BESIY

BMWYY

BURBY

CABGY

CABJF

CCHBF

CFRHF

CVVTF

CZMWF

CZMWY

DSDVF

DTEGF

DTEGY

DTRUY

FCHRF

HESAY

HSBC

IFNNF

IFNNY

IMBBY

KNYJF

LRLCF

LVMHF

LVMUY

MBGAF

MDIBF

MONRF

NONOF

NSRGF

NSRGY

NVSEF

POAHY

PPRUF

PROSY

PUBGY

RACE

RELX

RLXXF

RNKGF

RNMBF

RPYTF

SAUHF

SAUHY

SCBFF

SEBYF

SHEL

SKFRY

SLOIF

SSEZF

STMEF

SVCBF

SWGAY

TTFNF

UNCFF

UNCRY

VACNY

VOLAF

VTTGF

VWAGY

WKCMF

WTBCF

VAT Group

Intraday Update

ABNB

AFRM

ATHM

BCRX

BLMN

CABO

CARA

CPXWF

DNUT

EPAM

FAST

FREY

FSLR

GLOB

HOLI

IMMP

IMVT

IRDM

MGTA

MKTW

ODFL

PCSA

PFHD

PLAN

PLNT

SEDG

SKIL

TBLA

TCBK

TSCO

WELL

Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2021

Berenberg downgrades VAT Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VACNY#OTC">VACNY</a>) from Buy to Hold.

Berenberg Downgrades VAT Group to Hold

Comments

VAT Group

News

Latest news for VAT Group (OTC:VACNY) Stock

Tuesday, August 03, 2021

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga